Cited by 413Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Soria, Jean-Charles, Wu, Yi-Long, Nakagawa, Kazuhiko, Kim, Sang-We, Yang, Jin-Ji, Ahn, Myung-Ju, Wang, Jie, Yang, James Chih-Hsin, Lu, You, Atagi, Shinji, Ponce, Santiago, Lee, Dae Ho, Liu, Yunpeng, Yoh, Kiyotaka, Zhou, Jian-Ying, Shi, Xiaojin, Webster, Alan, Jiang, Haiyi, Mok, Tony S K·2015·The Lancet Oncology

DOI 10.1016/s1470-2045(15)00121-7

Open this paper in CoChat — free account

Abstract

Background Optimum management strategies for patients with advanced non-small-cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine-kinase inhibitors are undefined. We aimed to assess the efficacy and safety of continuing gefitinib combined with chemotherapy versus chemotherapy alone in patients with EGFR-mutation-positive advanced NSCLC with acquired resistance to first-line gefitinib.Methods The randomised, phase 3, multicentre IMPRESS study was done in 71 centres in 11 countries in Europe and the Asia-Pacific region. Eligible patients were aged at least 18 years with histologically confirmed, chemotherapy-naive, stage IIIB-IV EGFR-mutation-positive advanced NSCLC with previous disease control with first-line gefitinib and recent disease progression (Response Evaluation Criteria in Solid Tumors version 1.1). Participants were randomly assigned (1:1) by central block randomisation to oral gefitinib 250 mg or placebo once daily in tablet form; randomisation did not include stratification factors. All patients also received the platinum-based doublet chemotherapy cisplatin 75 mg/m(2) plus pemetrexed 500 mg/m(2) on the first day of each cycle. After completion of a maximum of six chemotherapy cycles, patients continued their randomly assigned treatment until disease progression or another discontinuation criterion was met. All study investigators and participants were masked to treatment allocation. The primary endpoint was progression-free survival in the intention-to-treat population. Safety was assessed in patients who received at least one dose of study treatment. The study has completed enrolment, but patients are still in follow-up for overall survival. This trial is registered with ClinicalTrials.gov, number NCT01544179.Findings Between March 29, 2012, and Dec 20, 2013, 265 patients were randomly assigned: 133 to the gefitinib group and 132 to the placebo group. At the time of data cutoff (May 5, 2014), 98 (74%) patients had disease progression in the gefitinib group compared with 107 (81%) in the placebo group (hazard ratio 0·86, 95% CI 0·65-1·13; p=0·27; median progression-free survival 5·4 months in both groups [95% CI 4·5-5·7 in the gefitinib group and 4·6-5·5 in the placebo group]). The most common adverse events of any grade were nausea (85 [64%] of 132 patients in the gefitinib group and 81 [61%] of 132 patients in the placebo group) and decreased appetite (65 [49%] and 45 [34%]). The most common adverse events of grade 3 or worse were anaemia (11 [8%] of 132 patients in the gefitinib group and five [4%] of 132 patients in the placebo group) and neutropenia (nine [7%] and seven [5%]). 37 (28%) of 132 patients in the gefitinib group and 28 (21%) of 132 patients in the placebo group reported serious adverse events.Interpretation Continuation of gefitinib after radiological disease progression on first-line gefitinib did not prolong progression-free survival in patients who received platinum-based doublet chemotherapy as subsequent line of treatment. Platinum-based doublet chemotherapy remains the standard of care in this setting.Funding AstraZeneca.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(15)00121-7

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Self-citation
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Self-citation
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090
Self-citation
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081
Self-citation
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citation

Show all 30 references

Sorted by citations

Items 301–400 of 411

Organometallic–Erlotinib Conjugates Active against Lung Cancer Cells and as Emerging Virus Entry Inhibitors
Biegański, P., Gazecka, M., Nowak, R., Gorski, A., Dutkiewicz, N., Kawano, D. F., Zmora, P., & Kowalski, K. (2024) · Organometallics · doi:10.1021/acs.organomet.4c00145 · Cited by 4
Continuing EGFR-TKI treatment in combination with super-selective arterial infusion chemotherapy beyond disease progression for patients with advanced EGFR-mutant non-small cell lung cancer
Qi, H., Jiang, S., Yu, D. H., Ni, H., Hu, Q., & Zhang, J. (2015) · Medical Oncology · doi:10.1007/s12032-015-0704-x · Cited by 4
“The main message from the recent IMPRESS trial [4] is that following disease progression on first-line EGFR-TKI therapy, a combination of systemic chemotherapy and EGFR-TKI therapy should not be used.”
Background
Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial
Yang, L., Yang, S., Liu, Y., Li, J., Hu, X., Wang, Y., Zhang, Y., & Wang, Y. (2018) · Thoracic Cancer · doi:10.1111/1759-7714.12632 · Cited by 4
Self-citation
A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
O'Brien, M. E. R., Sarker, D., Bhosle, J., Thillai, K., Yap, T. A., Uttenreuther‐Fischer, M., Pemberton, K., Jin, X., Wiebe, S. T., Bono, J. S. D., et al. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3661-1 · Cited by 4
“Conversely, in the phase III IMPRESS study, gefitinib plus cisplatin and pemetrexed in patients with EGFR mutationpositive advanced NSCLC and acquired resistance to firstline gefitinib did not prolong PFS in the overall population versus cisplatin plus pemetrexed [20].”
Background
Lung Adenocarcinoma
Patel, B. A., & Liu, S. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00006-7 · Cited by 4
A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations ( JMTO LC12 ‐01)
Asami, K., Ando, M., Nishimura, T., Yokoi, T., Tamura, A., Minato, K., Mori, M., Ogushi, F., Yamamoto, A., Yoshioka, H., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14465 · Cited by 3
“However, there was no benefit in continuing G in combination with a platinumdoublet chemotherapy for EGFR-mutant NSCLC in the IMPRESS study.(38) This study did not demonstrate the efficacy of continuing G in combination with chemotherapy after disease progression.”
BackgroundSelf-citation
Efficacy of targeted agents in the treatment of elderly patients with advanced non-small-cell lung cancer: a systematic review and meta-analysis
Chen, J., Chen, J., Wu, X., Shi, T., & Kang, M.-L. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s100618 · Cited by 4
Achievable complete remission of advanced non-small-cell lung cancer: Case report and review of the literature
Yang, N., Xiong, F., He, Q., & Guan, Y. (2018) · World Journal of Clinical Cases · doi:10.12998/wjcc.v6.i7.150 · Cited by 4
Immunotherapy in EGFR-Mutant Non–Small Cell Lung Cancer: End of the Road or the First Chapter?
Ketpueak, T., Tan, D. S. W., & Popat, S. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.00829 · Cited by 4
Case report: Aumolertinib plus gumarontinib in a patient with EGFR mutated non-small-cell lung cancer harboring acquired MET amplification following progression on afatinib plus crizotinib
Hui, J.-J., Ding, S., Qin, B., & Ding, N. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1525251 · Cited by 3
Gefitinib: an “orphan” drug for non-small cell lung cancer
Ziogas, D. C., Liontos, M., Kyriazoglou, A. I., Tsironis, G., Bamias, A., & Dimopoulos, M. A. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1392852 · Cited by 3
“In order to examine the continuation of gefitinib beyond resistance/progression, the IMPRESS trial compared gefitinib in combination with platinum-based chemotherapy versus chemotherapy alone in patients with EGFR-mutated advanced NSCLC with acquired resistance to first-line gefitinib, but no differences in progressio…”
Result
Osimertinib in first-line treatment—is a comparison not proof?
Cadranel, J. L. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.12.13 · Cited by 3
“In those trials, between 44% and 65% of patients were able to receive a second line of CT in the end (8-12), while the IMPRESS trial showed that CT (pemetrexed/platinum doublet and pemetrexed maintenance) resulted in a median PFS of 5 months in second-line treatment (26).”
Background
Guía SEOM-SERAM-SEMNIM sobre el empleo de las técnicas de imagen funcional y molecular en el cáncer de pulmón no microcítico avanzado
Pérez, G. F., Sánchez-Escribano, R., Vicente, A. M. G., Alcalá, A. L., Ceballos, J., Bolton, R. C. D., Busquets, J. C. V., Sánchez‐Rovira, P., Alanis, M. P. F., Figueiras, R. G., et al. (2018) · Radiología · doi:10.1016/j.rx.2018.01.007 · Cited by 3
A combined subtype of small cell lung cancer and adenocarcinoma with epidermal growth factor receptor (EGFR) mutation responds to EGFR tyrosine kinase inhibitors
Zhang, Y., Ye, L., Zhang, H., Chen, X., Ji, H., Chen, G., Zhang, L., Zhang, T., & Jin, M. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.09.101 · Cited by 3
“Patients harboring EGFR alterations benefit from gefitinib, a first generation of EGFR-TKI, and show promising partial responses (PR) (5-8).”
Background
A meta-analysis of the therapeutic effect of gefitinib combined with chemotherapy and chemotherapy alone in treating non-small cell lung cancer
Zhao, Q., Sun, K., Lei, X., & Cai, L. (2020) · Medicine · doi:10.1097/md.0000000000021490 · Cited by 3
“Two of the 7 trials were placebo-controlled double blind trials.([12,13]) Standard chemotherapeutic drugs included carboplatin and paclitaxel, cisplatin/carboplatin and pemetrexed, carboplatin and gemcitabine.”
BackgroundMethodInfluential
In silico screening of alkaloids as potential inhibitors of epidermal growth factor receptor
Tùng, B. T., Dung, P. T. K., Son, N. N., Kim, N. B., Hà, N. H., & Tra, N. T. (2023) · Ministry of Science and Technology Vietnam · doi:10.31276/vjste.65(3).85-90 · Cited by 3
Efficacy and safety of anti-programmed cell death protein 1 antibody combination therapy in patients with advanced experienced epidermal growth factor receptor-tyrosine kinase inhibitor-resistant lung adenocarcinoma: a retrospective cohort study
Wan, C., Zhang, Y., Liu, P., Mei, X., Cheng, G., Pang, J., Chen, S., Xu, J., Malhotra, J. D., Qian, H., et al. (2023) · Journal of Thoracic Disease · doi:10.21037/jtd-23-1399 · Cited by 3
RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report
Yan, H., Zeng, L., & Zhang, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29928 · Cited by 3
“Current research suggests that combination therapy with later-line chemotherapy and TKI may not improve the outcome [17], but this remains an area of exploration in the treatment of brain metastasis with TKIs.”
Background
Root Extract of Scutellaria Baicalensis Increases Gefitinib Sensitivity in H1975 Human Non-small Cell Lung Cancer Cells
Park, S., & Park, H.-J. (2021) · 동의생리병리학회지 · doi:10.15188/kjopp.2021.08.35.4.117 · Cited by 3
Continuation of Tyrosine Kinase Inhibitor is Associated with Survival Benefit in NSCLC Patients with Exon 19 Deletion after Solitary Progression
Na, F., Zhang, J., Deng, L., Zhou, X., Zhou, L., Zou, B., Yu, M., Li, Y., Xue, J., & Liu, Y. (2017) · Journal of Cancer · doi:10.7150/jca.20017 · Cited by 3
Self-citation
Patterns of Progression and Feasibility of Re-biopsy After First-line Erlotinib for Advanced EGFR Mutation-positive Non-small-cell Lung Cancer
Granados, A. L. O., Artal, A., Aguiar‐Bujanda, D., Oramás, J., Fírvida, J. L., de Castro, J., Fuentes, J. C., Gordo, R., Galán, R., Trigo, J. M., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13244 · Cited by 3
ORIENT-31 as the Sakigake “Charging Samurai” Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the “Meiji Modernization” of Post-3G EGFR TKI Progression?
Nagasaka, M., & Ou, S.-H. I. (2022) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s355503 · Cited by 3
“5 months).(19,20) Based on the results of IMPRESS, platinum-based chemotherapy was considered the SOC while continuation of the same EGFR TKI in combination of platinum-based chemotherapy post-progression EGFRTKI was discouraged.”
Result
The continued EGFR-TKI with cytotoxic chemotherapy at progression—poison or medicine?
Yoon, S., Choi, C., & Lee, J. C. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.03.23 · Cited by 3
“Further, more patients had brain metastases of unfavorable outcome in the gefitinib group (12).”
Background
Is Gefitinib Combined With Platinum-Doublet Chemotherapy a Counterpart to Osimertinib Monotherapy in Advanced EGFR-Mutated Non–Small-Cell Lung Cancer in the First-Line Setting?
Tanaka, T., Ishiki, H., Kubo, E., Yokota, S., Shimizu, M., Kiuchi, D., & Satomi, E. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02509 · Cited by 3
A highly annotated drug combination resource for catalyzing precision combinatorial therapy
You, T., Wang, L., Wang, J., Xu, D., Xu, X., Li, N., Li, M. J., Wang, H., & Dong, X. (2025) · Scientific Data · doi:10.1038/s41597-025-05630-4 · Cited by 3
“Another 13 drug combination data entries were collected from 13 reports published between 2010 and 2024 25–37 .”
Self-citation
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study
Nagashima, H., Fukuhara, T., Utsumi, Y., Suzuki, A. S., Miyanaga, A., Seike, M., Azuma, K., Asahina, H., Kisohara, A., Kawashima, Y., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115693 · Cited by 2
Impact of Market Access Delays on Time to Patient Access: Multi-Country Comparative Analysis Assessing the First Commercial Launch Indications for Five Oncology Medicines Across Europe and Canada
Crean, B., Parry, D., Horsfield, A., Ryan, J., & Oraiopoulos, N. (2026) · Journal of Market Access & Health Policy · doi:10.3390/jmahp14020025 · Cited by 2
“Table S1: Overview of the medicines evaluated in the study: indications at first major and supporting trials [6–13, 15– 23 , 25 , 38– 48 ].”
Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non–small Cell Lung Cancer
Wang, H., Zhang, M., Li, P., Zhang, G., Yan, X., & Ma, Z. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.027 · Cited by 2
Lazertinib versus Platinum-Based Chemotherapy with Epidermal Growth Factor Receptor (EGFR)-Positive Non-Small-Cell Lung Cancer after Failing EGFR-Tyrosine Kinase Inhibitor: A Real-World External Comparator Study
Lee, J. H., Lee, H., Yoon, D., Choi, E., Woo, J., Jo, B., Kim, S., Shin, J., & Jung, H. A. (2024) · Cancers · doi:10.3390/cancers16122169 · Cited by 2
“However, in previous retrospective studies of second-line therapy for EGFR-mutated NSCLC and IMPRESS, in which most patients were EGFR-T790M-negative, the median PFS for platinum-based chemotherapy was about 3–5.5 months [15–17].”
ResultInfluentialSelf-citation
ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC
Luukkainen, M. E. K., & Koivunen, J. P. (2024) · Anticancer Research · doi:10.21873/anticanres.17092 · Cited by 2
A study on the prediction of targeted therapy efficacy in advanced lung adenocarcinoma patients with EGFR mutations using CT-based delta-radiomics model
Wu, Z., Hua, P., Chen, X., Lei, J., Zhang, L., & Zhang, P. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1599206 · Cited by 2
The pharmacoeconomic efficacy of chemotherapy for malignant neoplasms of the bronchus and lung
Yarovoy, S. K., & Shikina, I. B. (2020) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909.2020.13.1.13-22 · Cited by 2
Chemotherapy (platinum and pemetrexed) in combination with erlotinib in non-small cell lung cancer induces major gastrointestinal toxicity: two case reports from the FLARE/GFPC 03-2013 study
Sassier, M., Peyro‐Saint‐Paul, L., Clarisse, B., Leconte, A., Coquerel, A., Alexandre, J., Fédrizzi, S., Leroy-Terquem, E., Madroszyk, A., & Gervais, R. (2016) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12406 · Cited by 2
“This decision was subsequently vindicated by the negative results of the IMPRESS study, which did not show any significant improvement in progression-free survival with continuation of gefitinib in addition to platinum-based doublet chemotherapy versus chemotherapy alone for patients with acquired resistance to firstl…”
ResultInfluential
Personalizing Therapy for Acquired Resistance to EGFR Kinase Inhibitors in Advanced NSCLC
Sacher, A. G., & Oxnard, G. R. (2016) · American Journal of Hematology / Oncology® · Cited by 2
Afatinib plus chemotherapy versus chemotherapy alone after progression on afatinib: new insights on old question?
Bhateja, P., & Sharma, N. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.09.45 · Cited by 1
Tratamiento de cáncer de pulmón metastásico (estadio IV) de célula no pequeña : consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO).
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Gómez, R., Lombana, M., Vargas, C., Duarte, R., Lobatón, J. F., Yepes, A., et al. (2018) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.364 · Cited by 2
RECENT ADVANCES IN DRUGS TARGETING PROTEIN KINASES FOR CANCER THERAPY.
Mahdy, H. A., Shaat, M., & Ayyad, R. R. A. (2022) · Al-Azhar Journal of Pharmaceutical Sciences/Al-Azhar Journal of Pharmaceutical Sciences · doi:10.21608/ajps.2022.268384 · Cited by 2
Continuous EGFR tyrosine kinase inhibitor treatment with or without chemotherapy beyond gradual progression in non-small cell lung cancer patients
Peng, L., Wang, Y., Tang, Y., Zeng, L., Liu, J., Zeng, Z., Liu, J., Shi, P., Ye, X., & Zhao, Q. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s143569 · Cited by 2
“Results of the IMPRESS trial found no statistically significant differences in median PFS and objective response between patients with acquired resistance to first line gefitinib who continued the same TKI after disease progression together with platinum doublet chemotherapy and those who received only chemotherapy.(2…”
Complexity in Clinical Trials: Blind Spots, Misleading Criteria, Winners and Losers
Yuan, G., Wang, L., Li, J., Feng, H., Ji, J., Gu, W., & Shan, B. (2019) · Clinical Cancer Drugs · doi:10.2174/2212697x06666191021125423 · Cited by 2
Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR : quels inhibiteurs ? Quelles séquences thérapeutiques ?
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2020) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(20)30100-2 · Cited by 2
Being molecular in the molecular age
Raghupathy, R., & Mok, T. S. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw002 · Cited by 2
“The concept of treatment beyond RECIST progression in EGFR mutant patients with advanced NSCLC was explored in the ASPIRATION study and in the IMPRESS study [11, 12].”
MethodSelf-citation
Cáncer de pulmón no microcítico
Expósito, F., González, J. L. L., Castillo, C., Losada, C. N., & Soto, M. Á.-M. (2017) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2017.04.001 · Cited by 1
Durvalumab, Tremelimumab, and Platinum Chemotherapy in EGFR Mutation–Positive NSCLC: An Open-Label Phase 2 Trial (ILLUMINATE)
Lee, C. K., Liao, B.-C., Subramaniam, S., Chiu, C., Mersiades, A. J., Ho, C., Brown, C. S. B., Lai, C., Hughes, B. G. M., Yang, T., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100771 · Cited by 1
Self-citation
Traitement standard des cancers bronchiques non à petites cellules métastatiques mutés EGFR en première ligne et à progression
Lefèvre, A., & Besse, B. (2025) · Bulletin du Cancer · doi:10.1016/s0007-4551(25)00160-2 · Cited by 1
Efficacy and safety analysis of treatment in patients with EGFR-mutated advanced NSCLC who progressed on TKIs: a systematic review and meta-analysis
Zhang, S., Li, R., Cui, H., & Li, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1673115 · Cited by 1
Anlotinib added to third generation EGFR tyrosine kinase inhibitor therapy for advanced NSCLC patients with oligo-progression: a retrospective study (ALTER-L058)
Zhou, F., Zhuo, M., Wang, H., Yang, N., Li, J., Shi, J., Han, Z., Zeng, G., Li, J., Song, Y., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1686364 · Cited by 1
Efficacy and safety of Chinese herbal medicine granules plus chemotherapy in patients with EGFR-mutated advanced lung adenocarcinoma post-progression on first-line EGFR-TKI: study protocol for a multicenter, double-blind, randomized controlled trial
Du, Y., Yao, J., Ye, X., Wu, G., Su, L., Yang, W., Jiao, L., Gong, Y., & Xu, L. (2025) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-025-05037-z · Cited by 1
“The IMPRESS study showed that the PFS for patients treated with cisplatin and pemetrexed post first-line EGFR-TKI resistance was a mere 5.4 months [15].”
Influential
Cytoskeletal remodeling via CAMSAP3 downregulation drives resistance to osimertinib in NSCLC cells
Yang, F., Wang, Z., Han, X., Zhong, J., Hou, Z., Bian, S., Long, J., & Liu, H. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08299-0 · Cited by 2
Real-World Clinical Outcomes and Treatment Patterns in Advanced/Metastatic EGFR-Mutant NSCLC After Progression on First-Line Osimertinib for French Patients
Girard, N., Macouillard, P., Byng, D., Meng, J., Coerts, F. B., Hunter, S. M., Strübing, A., Xiong, Y., Park, S., Haq, M. I., et al. (2026) · Advances in Therapy · doi:10.1007/s12325-025-03465-4 · Cited by 1
Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance
Niu, J., Jing, W., Liu, Z., Si, Y., & 刘寨东 (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1845547 · Cited by 1
“The IMPRESS study demonstrated that extending TKI therapy beyond resistance development, compared to chemotherapy, did not improve overall survival (OS) or PFS (24, 26).”
Discontinuing epidermal growth factor receptor-tyrosine kinase inhibitor during second-line chemotherapy: is the evidence strong enough?
Liang, W., He, Q., Chen, Y., Zou, X., Hamblin, L. T., & He, J. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.08.16 · Cited by 1
Continued EGFR Inhibition With Postprogression Chemotherapy: Where Do We Stand?
Piotrowska, Z., & Sequist, L. V. D. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0370 · Cited by 1
“[1] and the recently reported results of the larger IMPRESS trial [6] provide randomized, prospective data addressing the role of adding EGFR TKIs to postprogressionchemotherapyamongEGFR-mutant lungcancer patients.”
BackgroundResult
Les cancers bronchiques non à petites cellules EGFR-mutés
Baldacci, S., & Cortot, A. B. (2016) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(16)30126-4 · Cited by 1
Development and validation of a radiomics nomogram for progression-free survival prediction in stage IV EGFR-mutant non-small cell lung cancer
Song, J., Zang, Y., Li, W., Zhong, W., Shi, J., Dong, D., Fang, M., Liu, Z., & Tian, J. (2017) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.2253998 · Cited by 1
Concurrent Administration of an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor and Cytotoxic Anticancer Drug to Treat Epidermal Growth Factor Receptor Gene Mutation-positive and Mutation-negative Lung Cancers
Hirabae, A., Suzaki, N., Nagata, T., & Marukawa, M. (2018) · Haigan · doi:10.2482/haigan.58.127 · Cited by 1
Targeting Members of the Epidermal Growth Factor Receptor Family to Improve Response to Chemotherapy
O’Keefe, R. A., Grandis, J. R., & Johnson, D. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-813753-6.00001-9 · Cited by 1
Evaluation of Progression-Free Survival and Overall Survival of Epidermal Growth Factor Receptor-Positive Metastatic Lung Adenocarcinoma Patients Treated with Erlotinib
Shahriari, S., Seifi, S., Khodakarim, N., Ramim, T., & Dashtpeima, A. (2022) · Medical Journal of the Islamic Republic of Iran · doi:10.47176/mjiri.36.31 · Cited by 1
Safety Profile of Mutant EGFR-TK Inhibitors in Advanced Non–Small Cell Lung Cancer: A Meta-analysis
Tauseef, A. (2022) · Federal Practitioner · doi:10.12788/fp.0309 · Cited by 1
Combination of Osimertinib with Concurrent Chemotherapy and Hormonal Therapy for Synchronous NSCLC, Hormone Receptor-Positive Breast Cancer, and Triple-Negative Breast Cancer: Case Report
Park, C. L., Moria, F. A., & Saleh, R. (2023) · Case Reports in Oncology · doi:10.1159/000533783 · Cited by 1
“A similar study showed that continuing ge-ﬁ tinib, which is a ﬁ rst-generation EGFR TKI, in combination with chemotherapy at the time of progression did not yield synergistic adverse events, although this combination did not provide additional clinical bene ﬁ t [18].”
Background
Dynamic Analysis of the Impact of Micropapillary Component on Different Recurrence Patterns of Pathological Stage IA3 Lung Adenocarcinoma: A Multicenter, Retrospective Study
Xu, S., Chen, C., Tu, J.-H., You, C., Chen, R.-Q., Zhang, Z.-F., & Chen, S. (2023) · Annals of Surgical Oncology · doi:10.1245/s10434-023-14520-1 · Cited by 1
The History and Current State of EGFR-TKIs
Suda, K., & Mitsudomi, T. (2017) · Haigan · doi:10.2482/haigan.57.69 · Cited by 1
EGFR Targeted Therapy
Noor, Z. S., & Goldman, J. W. (2019) · Current cancer research · doi:10.1007/978-3-030-17832-1_1 · Cited by 1
Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses
Mazzanti, N. A., Scauri, C., Domini, B., Vassallo, C., Cusato, S., Fino, C. D., & de Marinis, F. (2019) · Global & Regional Health Technology Assessment · doi:10.1177/2284240319877892 · Cited by 1
The Efficacy of Pemetrexed-Based Therapy in Advanced Lung Adenocarcinoma with Targetable Driver Mutation: A Real-Life Experience
Bi̇lgi̇n, B., Yücel, Ş., & Yılmaz, Ü. (2020) · Journal of Oncological Sciences · doi:10.37047/jos.2020-73476 · Cited by 1
Prise en charge thérapeutique des cancers bronchiques non à petites cellules de stades avancés mutés pour l’EGFR
Cadranel, J. L., Fallet, V., Canellas, A., Lavolé, A., Ruppert, A.-M., & Wislez, M. (2018) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(18)30040-5 · Cited by 1
Advanced-Metastatic Non-Small-Cell Lung Cancer EGFR-mutated in Italy: patient management costs and potential productivity losses
Mazzanti, N. A., Scauri, C., Domini, B., Vassallo, C., Cusato, S., Fino, C. D., & de Marinis, F. (2019) · Global & Regional Health Technology Assessment · doi:10.33393/grhta.2019.451 · Cited by 1
Laying the Groundwork to Confront the Final Frontier of CNS Metastasis in NSCLC with Targetable Driver Mutations
Reungwetwattana, T., & Ou, S. I. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.005 · Cited by 1
“3% (75 of the 265 patients enrolled).(11) When these data are taken progressed while receiving first-line EGFR TKI, the proportion of patients with brain metastases doubled compared with the proportion of treatment-naive EGFRþ patients.”
Background
Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?
Salvia, A. L., Luca, E. D., Rossi, A., & Maïo, M. D. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1409721 · Cited by 1
“chemotherapy after progression to EGFR-TKIs in patients affected by EGFR mutation positive NSCLC, did not produce significant improvement in patients’ outcome [14].”
Background
Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié
Domblides, C. (2015) · HAL
Meta-analysis of the incidence and risk of arterial and venous thromboembolic events associated with anti-EGFR agents in non-small-cell lung cancer patients
Zheng, J., Bai, X., Hong, C., Gao, H., & Li, X. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2016.1220830
“[24] III Second line 265 Gefitinib + chemotherapy 60 5.”
Background
Therapy for EGFR tyrosine kinase inhibitor-resistant NSCLC with a focus on the T790M-resistant mutation
Zabernigg, A. F. (2016) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-016-0288-y
Resistance of Brain Tumours to Small-Molecule-Targeted Therapies: Lessons from Various Cancer Types
O’Neill, F. (2016) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-319-46505-0_5
A potential new therapeutic option for patients with advanced EGFR mutation-positive non-small cell lung cancer in first-line setting
Gridelli, C., & Losanno, T. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.11.91
Combination of EGFR-TKI and Platinum-based Therapy for EGFR-mutated Non-small Cell Lung Cancer
Oizumi, S. (2015) · Haigan · doi:10.2482/haigan.55.871
Osimertinib - a new treatment option for patients with EGFR mutation T790M
Svatoň, M., Hrdá, K., & Pešek, M. (2017) · Onkologie · doi:10.36290/xon.2017.015
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression
Hosomi, Y., Tanai, C., Yoh, K., Goto, Y., Sakai, H., Kato, T., Kaburagi, T., Nishio, M., Kim, Y. H., Inoue, A., et al. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1484903
“A randomized phase III study (IMPRESS) comparing continuation of gefitinib in combination with cisplatin and pemetrexed versus placebo plus cisplatin and pemetrexed as a second-line therapy in patients with EGFRm+ advanced NSCLC found no benefit of continuation of gefitinib in addition to platinum-based combination ch…”
BackgroundSelf-citation
The mechanisms of acquired resistance to anti-EGFR drugs in non-small cell lung cancer not associated with T790m mutation and their significance in clinical practice
Карабина, Е. В., Lubchenko, L. N., & Давыдов, М. М. (2018) · Advances in molecular oncology · doi:10.17650/2313-805x-2018-5-3-17-24
Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
Marcoux, N., & Sequist, L. V. D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-55433-6.00007-9
Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer
Ramalingam, S. S., Pillai, R. N., Reinmuth, N., & Reck, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-52357-8.00044-5
Gefitinib Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis
Shi, H. (2019) · Journal of Cancer Treatment and Research · doi:10.11648/j.jctr.20190701.13
A preliminary results of integrated chemotherapy with EGFR receptor tyrosine kinase inhibitors in patients with non-small-cell-lung cancer harboring EGFR mutation
Лактионов, К. К., Yudin, D. I., Breder, V. V., Реутова, Е. В., Павлович, Л. К., Тодорович, М. Д., Peregudov, D. A., & Сергеевич, А. М. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-10-110-114
New Approaches for the Treatment of Triple Negative Breast Cancer
Sulaiman, A. (2019) · uO Research (University of Ottawa) · doi:10.20381/ruor-23348
Traitement des cancers bronchiques non à petites cellules de stades avancés mutés EGFR: quelle(s) séquence(s) ?
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2019) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(19)30106-5
The evolution of views on the possibilities of drug therapy in overcoming acquired resistance not associated with Т790М mutation to anti-EGFR drugs in non-small cell lung cancer
Карабина, Е. В., Lubchenko, L. N., & Garunov, A. N. (2018) · Journal of Modern Oncology · doi:10.26442/1815-1434_2018.3.10-18
“При оценке показателя общей выживаемости (ОВ) в зависимости от статуса мутации Т790М сделан вывод о том, что продолжение терапии ИТК совместно с химиотерапией нецелесообразно [68].”
Tratamiento de cáncer de pulmón metastásico (estadio IV) : segundo consenso de expertos, Asociación Colombiana de Hematología y Oncología (ACHO), 2019.
Ospina, A. V., Bruges, R. E., Lema, M., Lopes, G. D. L., Jr., Provencio, M., Gómez, R., Lombana, M., Lobatón, J. F., Yepes, A., Abreo, D., et al. (2019) · Revista Colombiana de Hematología y Oncología · doi:10.51643/22562915.11
Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR
Cadranel, J. L., Fallet, V., Baldacci, S., & Cortot, A. B. (2021) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(21)00106-3
Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies
Cusano, E., Wong, C., Taguedong, E., Vaska, M. M., Abedin, T., Nixon, N. A., Karim, S., Tang, P. A., Heng, D. Y. C., & Ezeife, D. A. (2021) · Current Oncology · doi:10.3390/curroncol28060412
A Deep Learning solution for triaging patient with cancer from their predicted mutational status using histopathological imagesPreprint
Morel, L.-O., Dérangère, V., Arnould, L., Ladoire, S., & Vinçon, N. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.30.475484
Les cancers bronchiques non à petites cellules EGFR-mutés
Baldacci, S., Gervais, R., & Cortot, A. B. (2017) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(17)30054-x
The Role of Tyrosine Kinase Inhibitors in Reduction of Mortality from Non-small Cell Lung Cancer: A Meta-analysis
Zhang, X., & Lian, T. (2022) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207325666220701122755
Efficacy and Safety of Rezivertinib (BPI-7711) in Patients with Locally Advanced or Metastatic/Recurrent EGFR T790M Mutated NSCLC: A Phase IIb StudyPreprint
Shi, Y., Wu, S., Wang, K., Cang, S., Yao, W., Fan, Y., Wu, L., Huang, M., Li, X., Pan, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4106843
Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGR
Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00119-7 · Cited by 1
First-Third generation EGFR inhibitor combined with cytotoxic chemotherapy in elderly Patients with advanced lung adenocarcinom in routine clinical practice-results from A Subgroup Analysis
., A.-T. H. (2023) · Journal of Virology and Vaccination · doi:10.58489/2836-6387/002
Combination of Stereotactic Ablative Radiotherapy and Systemic Therapy in Oligoprogressive Non-small Cell Lung Cancer
Chicas-Sett, R., & Zafra, J. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_171
Targeted combination of Bevacizumab demonstrates superior efficacy for stage IV Adenocarcinoma of the lung with EGFR mutation: A Real World StudyPreprint
Yu, Y., Xu, L., Wei, X., Xie, H., Chen, Y., Li, H., Liu, Q., Sun, H., Ma, H., & Xing, W. (2023) · Research Square · doi:10.21203/rs.3.rs-3238070/v1
Epidermal growth factor receptor–mutated non–small cell lung cancer: a clinical approach
Roy, M., & Padda, S. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-69573-2.00019-x
Algorithme thérapeutique des cancers bronchiques non à petites cellules étendus avec mutation de l’EGFR
Cadranel, J. L., Fallet, V., Baldacci, S., Duruisseaux, M., & Cortot, A. B. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00139-8
Non-Invasive Tumor Immune Dysfunction and Exclusion Evaluation and Chemoimmunotherapy Response Prediction in Lung Adenocarcinoma Using Pathomic-Based ApproachPreprint
Nie, W., Zheng, L., Shen, Y., Zhang, Y., Teng, H., Zhong, R., Cheng, L., Tao, G., Han, B., Chu, T., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4827447
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series
Le, X., Eisert, A., Hsia, T., Raut, N. V., Ahmad, A. R., Chan, O. S. H., Bondt, C. D., Farrugia, D., Froesch, P., González‐Cao, M., et al. (2025) · Clinical Lung Cancer · doi:10.1016/j.cllc.2025.02.013
Radiomics based on MRI and 18F-FDG PET/CT predicts response to EGFR-TKI therapy based on primary NSCLC and brain metastasis
Fan, Y., Yang, C., Hu, Y., Zhao, P., Sun, Y., Jiang, M. C., Liu, Y., Wang, H., Jiang, X., Wang, Y., et al. (2025) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf100
“9 16 Previous studies showed the efficiency of radiomics in predicting therapeutic response to EGFR-TKIs based on thoracic CT 25,26,29 and PET 29 of the primary lesion, and MRI of BM. 20,21 While, whether the PET imaging of BM can provide predictive information regarding the response to EGFR-TKIs…”
Self-citation

Authors: Soria, J.-C., Wu, Y.-L., Nakagawa, K., Kim, S.-W., Yang, J.-J., Ahn, M.-J., Wang, J., Yang, J. C.-H., Lu, Y., Atagi, S., Ponce, S., Lee, D. H., Liu, Y., Yoh, K., Zhou, J.-Y., Shi, X., Webster, A., Jiang, H., & Mok, T. S. K.
Affiliations: Institut Gustave Roussy (FR)
Guangdong General Hospital (CN)
Kindai University (JP)
Asan Medical Center (KR)
National Taiwan University (TW)
Samsung Medical Center (KR)
Peking University Cancer Hospital (CN)
NHO Kinki Chuo Chest Medical Center (JP)
Hospital Universitario 12 De Octubre (ES)
First Hospital of China Medical University (CN)
National Cancer Center Hospital East (JP)
AstraZeneca (United Kingdom) (GB)
Chinese University of Hong Kong (HK)
Corresponding author: Mok, Tony S K
ORCID: Soria, Jean-Charles
Wu, Yi-Long
Nakagawa, Kazuhiko
Yang, Jin-Ji
Ahn, Myung-Ju
Wang, Jie
Yang, James Chih-Hsin
Atagi, Shinji
Ponce, Santiago
Liu, Yunpeng
Yoh, Kiyotaka
Shi, Xiaojin
Jiang, Haiyi
Mok, Tony S K
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2015-08
Volume: 16
Issue: 8
Pages: 990-998
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(15)00121-7
OpenAlex: W2152481222
Semantic Scholar: 8a3893572a340f3e2e3dc31440e3947d55eb0893
Cited by: 413
References: 30
Citations by year: 2026: 13 · 2025: 22 · 2024: 21 · 2023: 28 · 2022: 28 · 2021: 34 · 2020: 36 · 2019: 35 · 2018: 53 · 2017: 66 · 2016: 61 · 2015: 15
FWCI: 51.33
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Funders: AstraZeneca
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: gefitinib, EGFR mutation, non-small cell lung cancer, acquired resistance, EGFR tyrosine kinase inhibitors, cisplatin, pemetrexed, platinum-based chemotherapy, progression-free survival, second-line therapy, treatment safety, overall survival, quality of life, patient-reported outcomes, adverse events
MeSH terms: Pemetrexed, Gefitinib, Administration, Oral, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Asia, Carcinoma, Non-Small-Cell Lung, Cisplatin, Drug Administration Schedule, Europe, Female, Glutamates, Guanine, Humans, Infusions, Intravenous, Lung Neoplasms, Male, Middle Aged, Mutation, Phenotype, Prospective Studies, Quinazolines, Time Factors, Biomarkers, Tumor, Proportional Hazards Models, Treatment Outcome, Disease Progression, Disease-Free Survival, Genetic Predisposition to Disease, Protein Kinase Inhibitors, Kaplan-Meier Estimate, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks